Grass pollen allergy immunotherapy - Leti Pharma

Drug Profile

Grass pollen allergy immunotherapy - Leti Pharma

Alternative Names: Depigoid 34% GrassesMix/33% olea europaea/33% salsola kali; Depigoid Grass Mix; Depigoid Phleum pratense; Depigoid® Phleum; Modified allergen extract of Phleum pratense

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratorios LETI; LETI Pharma GmbH
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinoconjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 01 Aug 2016 LETI Pharma completes a phase II trial for Allergic conjunctivitis and Allergic rhinitis in Poland (EudraCT2014-004732-19)
  • 11 May 2016 An investigator completes a a phase II trial for Seasonal allergic rhinitis in Spain (SC) (EudraCT2010-020949-26)
  • 01 Aug 2015 Laboratorios LETI terminates a phase II trial in Seasonal allergic rhinitis and Allergic conjunctivitis in Spain (EudraCT2014-001571-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top